Serum prolactin level in patients taking olanzapine

Serum prolactin level in patients taking olanzapine

Introduction: Olanzapine is a commonly used antipsychotic. Prolactin elevation is a common adverse effect of anstipsychotics, and serum prolactin elevation is seen in about 30% patients treated with olanzapine. There are confounding results about dose dependency of olanzapine and prolactin elevation...

Full description

Bibliographic Details
Main Authors:	Diganta Das, Uddip Talukdar, Syed Javed Salman Chisty, Mantu Kumar Das, Shyamanta Das
Format:	Article
Language:	English
Published:	Academy Publisher 2015-01-01
Series:	Open Journal of Psychiatry and Allied Sciences
Subjects:	Psychotic Disorders Antipsychotic Agents Sex Blood Chemical Analysis
Online Access:	http://dysphrenia.hpage.co.in/ojpas-2015-6-50-58-fulltext_58801855.html

Similar Items

Use of Atypical Antipsychotics in Long-Term Care Residents with Parkinson’s Disease and Comorbid Depression
by: Chekani F, et al.
Published: (2020-01-01)

Comparison of the Effects of Clozapine, Olanzapine and Risperidone with Haloperidol on Fasting Blood Level of Glucose, Cholesterol and Triglyceride in Patients with Psychotic Disorders
by: A Masoudzadeh, et al.
Published: (2009-06-01)

Olanzapine-induced skin eruptions
by: Nishtha Chawla, et al.
Published: (2017-01-01)

"For the times they are a-changin'"
by: Shyamanta Das, et al.
Published: (2015-01-01)

Acute Generalized Exanthematous Pustulosis Induced by Olanzapine
by: Susanne Christen, et al.
Published: (2006-01-01)

Associations between symptom severity and well-being among Thai patients with schizophrenia: a cross-sectional analytical study
by: Teerapat Teetharatkul, et al.
Published: (2021-07-01)

An exploratory study from eastern India on neurological soft signs and spontaneous movement disorders in schizophrenia spectrum disorders
by: Shyamanta Das, et al.
Published: (2019-01-01)

Antipsychotic polypharmacy: Retrospective evaluation of cases with psychotic disorder followed in outpatient clinic (tur)
by: Şahabettin Çetin, et al.
Published: (2021-05-01)

A cross sectional study of trihexyphenidyl utilization on patient receiving antipsychotic therapy
by: Addiniya Nurul Azmi, et al.
Published: (2016-06-01)

Cigarette smoking and heavy coffee drinking affect therapeutic response to olanzapine
by: Radmanović Branimir, et al.
Published: (2018-01-01)

Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone Tranquilização rápida para pacientes agitados nos serviços de emergência psiquiátrica: um ensaio clínico randomisado de olanzapina, ziprasidona, haloperidol mais prometazina, haloperidol mais midazolam e haloperidol em monoterapia
by: Leonardo Baldaçara, et al.
Published: (2011-03-01)

Monitoring prolactin in patients taking antipsychotics
by: Aria Ghahramani, et al.
Published: (2024-01-01)

Sustained remission of psychotic symptoms secondary to hypothyroidism (myxedema psychosis) after 6 months of treatment primarily with levothyroxine: a case report
by: Eric C. Chan
Published: (2022-10-01)

Psychological intervention, antipsychotic medication or a combined treatment for adolescents with a first episode of psychosis: the MAPS feasibility three-arm RCT
by: Anthony P Morrison, et al.
Published: (2021-01-01)

Antipsychotic treatment patterns in refugees and their Swedish-born peers with first-episode non-affective psychosis: findings from the REMAIN study
by: Julia Spaton Goppers, et al.
Published: (2023-05-01)

Barriers to the management of sexual dysfunction among people with psychosis: analysis of qualitative data from the REMEDY trial
by: Lavanya J. Thana, et al.
Published: (2022-08-01)

The comparative efficacy of Haloperidol (IM) plus Lorazepam (PO) and Risperidon plus Lorazepam in the management of acute agitation
by: H.Toofanei (M.D), et al.
Published: (2002-09-01)

Association between the HTR2C rs1414334 C/G gene polymorphism and the development of the metabolic syndrome in patients treated with atypical antipsychotics
by: José María Rico-Gomis, et al.
Published: (2016-07-01)

Paliperidone to Treat Psychotic Disorders
by: Hormazd D. Minwalla, et al.
Published: (2021-07-01)

Pulmonary thromboembolism and sudden death in psychiatric patients: Two cases reports
by: Marinković Nadica, et al.
Published: (2017-01-01)

Pharmacogenetics biomarkers of antipsychotics’ safety in adolescents with acute psychotic episode
by: D. V. Ivashchenko, et al.
Published: (2019-12-01)

Impact of diagnosis on outcomes for compulsory treatment orders in New Zealand
by: Ben Beaglehole, et al.
Published: (2022-09-01)

A single-blind, randomised controlled trial of a physical health nurse intervention to prevent weight gain and metabolic complications in first-episode psychosis: the Physical Health Assistance in Early Psychosis (PHAstER) study
by: Brian O'Donoghue, et al.
Published: (2022-11-01)

Plasma Levels of Long-Acting Injectable Antipsychotics in Outpatient Care: A Retrospective Analysis
by: Hýža M, et al.
Published: (2021-04-01)

Olanzapine in the treatment of anorexia nervosa: a systematic review
by: Sidar Çöpür, et al.
Published: (2020-06-01)

Olanzapine induced tardive dyskinesia
by: Rudraprosad Chakraborty, et al.
Published: (2014-01-01)

Olanzapine-induced neutropenia
by: Kirti Malhotra, et al.
Published: (2015-06-01)

Application of a Pharmacogenetics-Based Precision Medicine Model (5SPM) to Psychotic Patients That Presented Poor Response to Neuroleptic Therapy
by: Lorena Carrascal-Laso, et al.
Published: (2020-12-01)

A Case-control Study of Sexual Dysfunction and Serum Prolactin Levels in Patients with Psychotic Disorders
by: Mohd Rashid Alam, et al.
Published: (2022-05-01)

Association of serum brain‐derived neurotrophic factor level and early response to antipsychotic drug in first‐episode patients with schizophrenia
by: Tong Zhao, et al.
Published: (2024-03-01)

Assessment of quality of life in patients with alcohol dependence syndrome
by: Gopal Das Mohan Das Chikkerahally
Published: (2019-01-01)

Olanzapine-induced neuroleptic malignant syndrome
by: Pradeep Kumar Saha, et al.
Published: (2017-01-01)

Prevalence of thyroid disorders among pregnant women in lower Assam
by: Diganta Das, et al.
Published: (2021-01-01)

Obesity and bariatric surgery in adults living with severe mental illness: perceptions and clinical challenges
by: Carolina Pressanto, et al.
Published: (2023-06-01)

An intercultural perspective toward supporting antipsychotic medication adherence in clinical practice
by: Tharun Zacharia
Published: (2023-02-01)

The polymorphic variants DRD2 rs1800497 and ABCB1 3435C>T are associated with antipsychotic safety parameters in adolescents with an acute psychotic episode: the results of a pilot study
by: D. V. Ivashchenko, et al.
Published: (2020-10-01)

Case report: Successful administration of cariprazine in a young, severely ill patient with recurrent relapses of schizophrenia and persistent negative symptoms
by: Jelena Vrublevska
Published: (2023-03-01)

Economic Impact of the Application of a Precision Medicine Model (5SPM) on Psychotic Patients
by: Carrascal-Laso L, et al.
Published: (2021-08-01)

Analisi farmacoeconomica del trattamento di pazienti psicotici cronici con olanzapina, antipsicotici atipici e neurolettici tipici: uno studio regionale
by: Felice Vadruccio, et al.
Published: (2005-06-01)

Cardiovascular risk screening of patients with serious mental illness or use of antipsychotics in family practice
by: Kirsti M. Jakobs, et al.
Published: (2020-07-01)